Johnson & Johnson (JNJ) Non-Current Deffered Revenue (2009)
Johnson & Johnson (JNJ) posted Non-Current Deffered Revenue of $7.1 billion for Q3 2009, down 3.51% sequentially from $7.4 billion in Q2 2009.
Johnson & Johnson (JNJ) Non-Current Deffered Revenue (2009) Analysis & Trends
Johnson & Johnson has reported Non-Current Deffered Revenue for 1 years, with the latest figure at $7.1 billion in Q3 2009.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 27, 2009 | 7.11 Bn |
| Jun 28, 2009 | 7.37 Bn |